Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group. Mayer-Hamblett N, et al. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1177-1187. doi: 10.1164/rccm.201802-0215OC. Am J Respir Crit Care Med. 2018. PMID: 29890086 Free PMC article. Clinical Trial.
Vascular anomaly: Cause of infant respiratory distress and dysphagia.
Baig A, Fortner C, Rivera M, Merrow J, Gupta S, Sher E, Mortelliti A. Baig A, et al. Among authors: fortner c. Respir Med Case Rep. 2019 Jul 16;28:100908. doi: 10.1016/j.rmcr.2019.100908. eCollection 2019. Respir Med Case Rep. 2019. PMID: 31367518 Free PMC article.
Variability in evaluation and follow-up of newborns with CRMS/CFSPID in New York State.
Kier C, Kay DM, Langfelder-Schwind E, Goetz DM, Berdella M, DeCelie-Germana JK, Soultan ZN, Caggana M, Fortner CN, Giusti R, Kaslovsky R, Voter K, Welter JJ; New York State Cystic Fibrosis Newborn Screening Consortium; Sadeghi H. Kier C, et al. Among authors: fortner cn. Pediatr Pulmonol. 2024 Mar 1. doi: 10.1002/ppul.26928. Online ahead of print. Pediatr Pulmonol. 2024. PMID: 38426813 No abstract available.
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group. Davies JC, et al. N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334693 Free PMC article. Clinical Trial.
Advances in oncology pharmacy practice.
Shank BR, Schwartz RN, Fortner C, Finley RS. Shank BR, et al. Among authors: fortner c. Am J Health Syst Pharm. 2015 Dec 1;72(23):2098-100. doi: 10.2146/ajhp150637. Am J Health Syst Pharm. 2015. PMID: 26581937 No abstract available.
Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor.
Carlson DA, Franke AS, Weitzel DH, Speer BL, Hughes PF, Hagerty L, Fortner CN, Veal JM, Barta TE, Zieba BJ, Somlyo AV, Sutherland C, Deng JT, Walsh MP, MacDonald JA, Haystead TA. Carlson DA, et al. Among authors: fortner cn. ACS Chem Biol. 2013 Dec 20;8(12):2715-23. doi: 10.1021/cb400407c. Epub 2013 Oct 17. ACS Chem Biol. 2013. PMID: 24070067 Free PMC article.
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, Aubry MC, Tang H, Yi ES. Yang P, et al. Among authors: fortner c. J Thorac Oncol. 2012 Jan;7(1):90-7. doi: 10.1097/JTO.0b013e31823c5c32. J Thorac Oncol. 2012. PMID: 22134072 Free PMC article.
Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension.
Sparks MA, Parsons KK, Stegbauer J, Gurley SB, Vivekanandan-Giri A, Fortner CN, Snouwaert J, Raasch EW, Griffiths RC, Haystead TA, Le TH, Pennathur S, Koller B, Coffman TM. Sparks MA, et al. Among authors: fortner cn. Hypertension. 2011 Mar;57(3):577-85. doi: 10.1161/HYPERTENSIONAHA.110.165274. Epub 2011 Jan 17. Hypertension. 2011. PMID: 21242463 Free PMC article.
Deletion of the protein kinase A/protein kinase G target SMTNL1 promotes an exercise-adapted phenotype in vascular smooth muscle.
Wooldridge AA, Fortner CN, Lontay B, Akimoto T, Neppl RL, Facemire C, Datto MB, Kwon A, McCook E, Li P, Wang S, Thresher RJ, Miller SE, Perriard JC, Gavin TP, Hickner RC, Coffman TM, Somlyo AV, Yan Z, Haystead TA. Wooldridge AA, et al. Among authors: fortner cn. J Biol Chem. 2008 Apr 25;283(17):11850-9. doi: 10.1074/jbc.M708628200. Epub 2008 Feb 29. J Biol Chem. 2008. PMID: 18310078 Free PMC article.
ROCK1 phosphorylates and activates zipper-interacting protein kinase.
Hagerty L, Weitzel DH, Chambers J, Fortner CN, Brush MH, Loiselle D, Hosoya H, Haystead TAJ. Hagerty L, et al. J Biol Chem. 2007 Feb 16;282(7):4884-4893. doi: 10.1074/jbc.M609990200. Epub 2006 Dec 8. J Biol Chem. 2007. PMID: 17158456 Free article.
Aquaporin 5-deficient mouse lungs are hyperresponsive to cholinergic stimulation.
Krane CM, Fortner CN, Hand AR, McGraw DW, Lorenz JN, Wert SE, Towne JE, Paul RJ, Whitsett JA, Menon AG. Krane CM, et al. Among authors: fortner cn. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14114-9. doi: 10.1073/pnas.231273398. Epub 2001 Nov 13. Proc Natl Acad Sci U S A. 2001. PMID: 11707570 Free PMC article.
Phase I trial of N-methylformamide (NMF, NSC 3051).
O'Dwyer PJ, Donehower M, Sigman LM, Fortner CL, Aisner J, Van Echo DA. O'Dwyer PJ, et al. Among authors: fortner cl. J Clin Oncol. 1985 Jun;3(6):853-7. doi: 10.1200/JCO.1985.3.6.853. J Clin Oncol. 1985. PMID: 4009219
Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
De Jongh CA, Wade JC, Schimpff SC, Newman KA, Finley RS, Salvatore PC, Moody MR, Standiford HC, Fortner CL, Wiernik PH. De Jongh CA, et al. Among authors: fortner cl. Am J Med. 1982 Jul;73(1):89-96. doi: 10.1016/0002-9343(82)90935-4. Am J Med. 1982. PMID: 6211981 Clinical Trial.
High-dose methotrexate with folinic acid rescue.
Bender JF, Grove WR, Fortner CL. Bender JF, et al. Among authors: fortner cl. Am J Hosp Pharm. 1977 Sep;34(9):961-5. Am J Hosp Pharm. 1977. PMID: 333910 Review.
Carcinoma of the breast.
Grove WR, Fortner CL. Grove WR, et al. Among authors: fortner cl. J Am Pharm Assoc. 1976 May;16(5):254-62. doi: 10.1016/s0003-0465(16)33571-6. J Am Pharm Assoc. 1976. PMID: 774002 Review. No abstract available.
Cost analysis of leukemia treatment: a problem-oriented approach.
Esterhay RJ Jr, Vogel VG, Fortner CL, Shapiro HM, Wiernik PH. Esterhay RJ Jr, et al. Among authors: fortner cl. Cancer. 1976 Feb;37(2):646-52. doi: 10.1002/1097-0142(197602)37:2<646::aid-cncr2820370206>3.0.co;2-l. Cancer. 1976. PMID: 814993
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, O'Connell MJ, Fortner C. Wiernik PH, et al. Among authors: fortner c. Cancer Treat Rep. 1976 Jan;60(1):41-53. Cancer Treat Rep. 1976. PMID: 1069608 Clinical Trial.
Hodgkin's disease.
Cornelis WA, Christian DG, Fortner CL. Cornelis WA, et al. Among authors: fortner cl. J Am Pharm Assoc. 1973 Mar;13(3):147-54. doi: 10.1016/s0003-0465(16)32524-1. J Am Pharm Assoc. 1973. PMID: 4689937 No abstract available.
Allopurinol-mercaptopurine interaction.
Weissman AM, Christian DG, Cornelis WA, Fortner CL. Weissman AM, et al. Among authors: fortner cl. J Am Pharm Assoc. 1973 Jan;13(1):2. J Am Pharm Assoc. 1973. PMID: 4682571 No abstract available.
The acute leukemias.
Christian DG, Cornelis WA, Fortner CL. Christian DG, et al. Among authors: fortner cl. J Am Pharm Assoc. 1972 Sep;12(9):473-81. doi: 10.1016/s0003-0465(16)32344-8. J Am Pharm Assoc. 1972. PMID: 5052958 No abstract available.